SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlist Inc. is experiencing a surge in investor sentiment and trading volume driven by a major patent cross-licensing agreement with Samsung, which has bolstered the company's financial position and market standing. The community is heavily focused on the stock's potential for a short squeeze, its pending legal battles against other tech giants, and the anticipation of a future Nasdaq uplisting.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently trading at decade lows, fueling intense debate between retail investors eyeing a value opportunity and those concerned that structural shifts in consumer demand and market share losses justify the downward trend. While the community is actively discussing potential catalysts like tariff refunds and buyback potential, sentiment remains deeply divided as the stock struggles to find a sustained recovery floor.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as users report frustration with platform outages and login issues that have disrupted trading activity. Beyond technical concerns, the community is actively discussing the firm's competitive position against newer brokerage apps and its recent push into cryptocurrency trading.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as retail sentiment shifts heavily bullish following a significant competitive-elimination catalyst, as rival EyePoint's Phase III wet AMD trial missed its primary endpoint. Investors are actively discussing the possibility of a buyout and the removal of key legal and commercial hurdles, with the community closely tracking upcoming institutional developments and potential NDA paths.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and social media users weigh the company's financial future against ongoing political debates. Discussions remain heavily polarized, with community members debating the impact of the current political environment, corporate leadership, and potential for future volatility.

Duos Technologies Group, Inc. designs, develops, deploys, and operates intelligent technology solutions supporting rail, logistics, intermodal and government customers that streamlines operations, improves safety and reduces costs. It offers imaging, safety and security, software, and services. The firm also provides cutting edge solutions that automate the mechanical and security inspection of fast moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. The company was founded on May 31, 1994 and is headquartered in Jacksonville, FL.

Duos Technologies Group Inc

Duos Technologies is capturing investor interest following significant infrastructure deals, including a five-year, 55 MW hosting agreement with Axe Compute valued at over $500 million. The community is actively discussing the company's strategic pivot toward AI-ready modular edge data centers as a solution to the broader industry's power and interconnection bottlenecks.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is facing intense bearish sentiment from the community due to ongoing cash burn concerns and skepticism regarding the company's ability to achieve profitability through the R2 launch. While some investors are pointing to high reservation counts and strategic institutional support as long-term catalysts, the stock continues to struggle with weak volume and consistent selling pressure that has traders deeply divided over its near-term prospects.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is seeing significant attention as investors speculate on the upcoming spin-off and potential IPO of its AI chip subsidiary, Kunlunxin, while also tracking its strategic integration of AI models into major tech ecosystems. Community sentiment remains polarized, with some bullish traders focusing on these specific AI-driven catalysts, while others emphasize broader concerns regarding the volatility of Chinese ADRs and geopolitical regulatory risks.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors react to positive mechanistic insights regarding its pipeline, fueling optimism ahead of the Q4 BLA submission for its prostate cancer drug. The community is actively discussing the platform's potential, strong institutional backing, and a significant market opportunity that has sparked widespread interest in the company's long-term commercial trajectory.

Aventus Network

Aventus Network is experiencing heightened volatility and community debate as traders react to reported changes in supply and circulating token dynamics. Investors are actively discussing the potential for recovery and speculative growth while navigating platform-specific buying constraints and reports of significant whale activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PHVS New PDUFA Date 2027-04-23 Pharvaris N.V. Link:https://www.globenewswire.com/news-release/2026/07/06/3322293/0/en/pharvaris-announces-fda-acceptance-of-new-drug-application-for-deucrictibant-ir-for-on-demand-treatment-of-hereditary-angioedema-attacks.html Calendar:http://www.fdatracker.com/fda-calendar/

If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacksNDA includes positive data from successful clinical...

GlobeNewswire News Room

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

This calendar tracks upcoming PDUFA drug approval dates and FDA advisory committee meetings. Sign up or log in to access our Enhanced FDA Calendar! Our enhanced FDA calendar integrates PDUFA dates, clinical trial primary completion dates, and working capital runway estimates into a single timeline that covers companies publicly traded in the U.S.

Fdatracker

FDA Calendar

StockTwits Web

Pharvaris NV

 New PDUFA Date 2027-04-23 Pharvaris N.V. Link: